查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1462685

犬关节炎治疗的全球市场预测（-2030）：按类型、治疗类型、给药途径、通路和区域进行分析

Canine Arthritis Treatment Market Forecasts to 2030 - Global Analysis By Type, By Treatment Type, Route of Administration, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

2023年全球犬关节炎治疗市场规模为23亿美元，预计2030年将达32亿美元，预测期内复合年增长率为5.2%。犬关节炎治疗包括多种控制关节炎犬疼痛和发炎的方法。

其中包括非类固醇消炎剂(NSAID) 等药物、葡萄糖胺和软骨素等补充品、物理治疗、体重管理和生活方式改变。在严重的情况下，可能需要手术。目标是改善活动能力、减少不适并提高患者的生活品质。

根据美国宠物产品协会的数据，2017 年美国家庭中估计有 9,420 万隻猫和 8,970 万隻狗。

宠物拥有量和宠物医疗保健支出的增加

全球养宠物的趋势不断增长，对犬关节炎治疗市场的成长做出了重大贡献。随着越来越多的人将宠物视为家庭的重要成员，宠物医疗保健的支出也相应增加，包括治疗狗关节炎等疾病。宠物饲主越来越愿意投资先进的医疗保健和疗法，以确保宠物的健康和福祉，这推动了对创新治疗方法的需求，并增加了整体市场的成长。

与先进治疗方案相关的高成本

干细胞疗法和整形外科手术等先进治疗方案的高昂费用给寻求犬类关节炎综合治疗的宠物饲主带来了巨大的经济障碍。这些先进的治疗方法往往需要花费大量金钱，并且会阻碍患者接受治疗。因此，宠物饲主可能会转向更便宜的替代品，或者由于经济限製而完全放弃治疗。这种负担能力的挑战凸显了对易于使用且具有成本效益的解决方案的需求，以确保为患有关节炎的宠物提供最佳护理。

对微创治疗方案的需求不断增长

宠物饲主越来越多地寻求微创手术，以提供更快的恢復时间并降低宠物出现併发症的风险。关节镜和雷射治疗等微创技术因其有效性和对宠物生活方式的影响极小而越来越受欢迎。这一趋势为兽医医院和製造商提供了开发和提供创新的微创治疗方法的机会，以满足饲主及其患有关节炎的宠物不断变化的需求。

与某些治疗方法相关的潜在副作用和风险

非类固醇消炎剂(NSAID) 和皮质类固醇等治疗可以缓解症状，但也可能引起副作用，例如胃肠道问题和肾臟併发症。这些风险可能会阻止饲主选择这些治疗方法，并影响他们选择传统治疗方法的意愿。因此，确保犬关节炎治疗的安全性和有效性对于减少对市场接受度和宠物福祉的潜在威胁至关重要。

COVID-19 的影响：

COVID-19 大流行改变了兽医护理和宠物饲养行为，从而影响了犬类关节炎治疗市场。对非必要服务的限制和经济的不确定性减少了兽医诊所的就诊次数，影响了诊断和治疗。此外，财务限制影响宠物饲主投资先进治疗的意愿，影响市场成长并凸显对负担得起的治疗选择的需求。

非类固醇消炎剂（NSAID）部分预计在预测期内达到最大值

在预测期内，预计犬类关节炎治疗市场将由非类固醇消炎剂（NSAID）领域主导。这种优越性归因于多种因素，包括其广泛用作治疗狗关节炎相关疼痛和发炎的传统治疗选择。此外，与其他先进治疗方法相比，非类固醇消炎剂因其有效性和相对较低的成本而经常受到兽医的青睐，从而使其占据市场主导地位。

注射剂领域预计在预测期内复合年增长率最高

在犬关节炎治疗市场中，注射剂市场预计将在预测期内实现最高成长。这种增长归因于多种因素，包括给药便利性、标靶治疗的功效以及创新註射疗法的开发。此外，配方技术的进步和向微创治疗的转变正在推动对注射剂的需求，并且是预计导致快速增长的因素。

比最大的地区

预计在预测期内，北美将主导犬类关节炎治疗市场。这是由于宠物饲主数量众多、可支配收入高、兽医医疗基础设施发达以及研发进步。此外，人们对宠物健康意识的增强以及像对待人类一样对待宠物的趋势也进一步促进了该地区的崛起。因此，在可预见的未来，北美预计将保持在犬类关节炎治疗市场的主导地位。

复合年增长率最高的地区：

在预测期内，亚太地区的犬关节炎治疗市场可望快速成长。这是由于宠物拥有量的增加、可支配收入的增加以及宠物保健意识的提高，这些都推动了对关节炎治疗的需求。此外，兽医基础设施的改善和先进治疗方法的采用正在提高治疗的可及性。因此，亚太地区为市场扩张、吸引投资和促进犬关节炎治疗解决方案的创新提供了重大机会。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场公司的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球犬关节炎治疗市场：依类型

  • 骨关节炎
  • 类风湿性关节炎
  • 幼年特发性关节炎

第六章全球犬关节炎治疗市场：依治疗类型

  • 非类固醇消炎剂(NSAID)
  • 缓解疾病抗风湿药物 (DMARD)
  • 皮质类固醇
  • 营养补充食品
  • 物理治疗与復健
  • 干细胞疗法
  • 外科手术
  • 其他治疗类型

第七章全球犬关节炎治疗市场：依给药途径

  • 口服
  • 注射
  • 局部的

第八章全球犬关节炎治疗市场：按分销管道

  • 动物诊所/医院
  • 零售药房
  • 网路药房

第九章全球犬关节炎治疗市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第10章 主要进展

  • 协议、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • Boehringer Ingelheim Animal Health
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health
  • Hill's Pet Nutrition
  • InVivo Therapeutics Corporation
  • Mars Petcare
  • Merck Animal Health
  • Norbrook Laboratories
  • Nutramax Laboratories, Inc.
  • OrthoPets LLC
  • Rejuvenate Bio
  • Royal Canin
  • Veterinary Orthopedic Implants Inc.
  • Vetoquinol SA
  • Virbac
  • Zoetis Inc.
Product Code: SMRC25736

According to Stratistics MRC, the Global Canine Arthritis Treatment Market is accounted for $2.3 billion in 2023 and is expected to reach $3.2 billion by 2030 growing at a CAGR of 5.2% during the forecast period. Canine arthritis treatment involves various approaches to managing pain and inflammation in dogs affected by arthritis. These may include medication such as nonsteroidal anti-inflammatory drugs (NSAIDs), supplements like glucosamine and chondroitin, physical therapy, weight management, and lifestyle modifications. In severe cases, surgery may be necessary. The goal is to improve mobility, reduce discomfort, and enhance the quality of life for affected dogs.

According to the American Pet Products Association, an estimated 94.2 million cats and 89.7 million dogs are owned by households in the U.S. during 2017.

Market Dynamics:

Driver:

Rising pet ownership and expenditure on pet healthcare

The increasing trend of pet ownership worldwide has significantly contributed to the growth of the canine arthritis treatment market. As more people embrace pets as integral members of their families, there's a corresponding rise in expenditure on pet healthcare, including treatment for conditions like canine arthritis. Pet owners are increasingly willing to invest in advanced medical care and therapies to ensure the health and well-being of their furry companions, driving demand for innovative treatments and boosting the overall market for canine arthritis treatment.

Restraint:

High cost associated with advanced treatment options

The high cost associated with advanced treatment options, such as stem cell therapy and orthopedic surgeries, presents a significant financial barrier for pet owners seeking comprehensive care for canine arthritis. These advanced treatments often entail substantial expenses, potentially deterring individuals from pursuing them. Consequently, pet owners may resort to less expensive alternatives or even forego treatment altogether due to financial constraints. This affordability challenge underscores the need for accessible and cost-effective solutions to ensure optimal care for pets suffering from arthritis.

Opportunity:

Growing demand for minimally invasive treatment options

Pet owners are increasingly seeking less invasive procedures that offer quicker recovery times and reduce the risk of complications for their furry companions. Minimally invasive techniques, such as arthroscopy and laser therapy, are gaining popularity due to their efficacy and minimal disruption to the pet's lifestyle. This trend presents an opportunity for veterinary clinics and manufacturers to develop and offer innovative, minimally invasive treatments to meet the evolving needs of pet owners and their arthritic pets.

Threat:

Potential side effects and risks associated with certain treatment modalities

Treatments like non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids can alleviate symptoms, but they may also lead to adverse reactions such as gastrointestinal issues or renal complications. Such risks may deter pet owners from pursuing these treatments, impacting their willingness to opt for conventional therapies. Consequently, ensuring the safety and efficacy of canine arthritis treatments is essential to mitigating potential threats to market acceptance and pet well-being.

Covid-19 Impact:

The COVID-19 pandemic has influenced the canine arthritis treatment market by altering veterinary care access and pet ownership behaviors. Restrictions on non-essential services and economic uncertainties have led to decreased veterinary visits, affecting diagnosis and treatment. Additionally, financial constraints have influenced pet owners' willingness to invest in advanced treatments, impacting market growth and emphasizing the need for affordable care options.

The nonsteroidal anti-inflammatory drugs (NSAIDs) segment is expected to be the largest during the forecast period

In the canine arthritis treatment market, the nonsteroidal anti-inflammatory drugs (NSAIDs) segment is projected to dominate during the forecast period. This dominance can be attributed to several factors, including their widespread use as a conventional treatment option for managing arthritis-related pain and inflammation in dogs. Additionally, NSAIDs are often preferred by veterinarians due to their efficacy and relatively low cost compared to other advanced treatment modalities, contributing to their anticipated prominence in the market.

The injectables segment is expected to have the highest CAGR during the forecast period

In the canine arthritis treatment market, the injectables segment is projected to experience the highest growth during the forecast period. This growth is attributed to several factors, including the convenience of administration, efficacy in delivering targeted treatment, and the development of innovative injectable therapies. Additionally, advancements in formulation technologies and a shift towards minimally invasive treatment options are driving the demand for injectables, contributing to their anticipated rapid growth trajectory.

Region with largest share:

Over the forecast period, North America is poised to dominate the canine arthritis treatment market. This is due to a large population of pet owners with high disposable income, a well-established veterinary healthcare infrastructure, and advanced research and development activities. Additionally, increasing awareness about pet health and a growing trend towards the humanization of pets further contribute to the region's prominence. Consequently, North America is expected to maintain its leading position in the canine arthritis treatment market in the foreseeable future.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is poised for rapid growth in the canine arthritis treatment market. This is due to increasing pet ownership rates, rising disposable incomes, and growing awareness of pet healthcare, which are driving demand for arthritis treatments. Additionally, improving veterinary infrastructure and the adoption of advanced treatment modalities are enhancing accessibility to care. As a result, the Asia-Pacific region presents significant opportunities for market expansion, attracting investments, and fostering innovation in canine arthritis treatment solutions.

Key players in the market

Some of the key players in Canine Arthritis Treatment Market include Boehringer Ingelheim Animal Health, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health, Hill's Pet Nutrition, InVivo Therapeutics Corporation, Mars Petcare, Merck Animal Health, Norbrook Laboratories, Nutramax Laboratories, Inc., OrthoPets LLC, Rejuvenate Bio, Royal Canin, Veterinary Orthopedic Implants Inc., Vetoquinol S.A., Virbac and Zoetis Inc.

Key Developments:

In February 2024, Rejuvenate Bio partnered with a leading animal health company to develop and commercialize groundbreaking gene therapy for canine osteoarthritis, aiming to address the condition's widespread prevalence and devastating consequences, potentially revolutionizing dog health. This agreement with the global company follows the agreement reached in 2022 with Phibro Animal Health and further validates the gene therapy technology developed by Rejuvenate Bio and their strategy to develop their breakthrough technology in both animal health and human health.

In May 2023, The Food and Drug Administration (FDA) approved Librela, for the control of canine OA pain in the U.S. The first and only injectable monoclonal antibody (mAb) treatment for canine OA is expected to be available in late 2023. A once-monthly injection administered by a veterinary professional, Librela (bedinvetmab injection) works differently than other pain medications, according to a May 5 release from Zoetis.

Types Covered:

  • Osteoarthritis
  • Rheumatoid Arthritis
  • Juvenile Idiopathic Arthritis

Treatment Types Covered:

  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Disease-Modifying Antirheumatic Drugs (DMARDs)
  • Corticosteroids
  • Nutraceuticals
  • Physical Therapy and Rehabilitation
  • Stem Cell Therapy
  • Surgery
  • Other Treatment Types

Route of Administrations Covered:

  • Oral
  • Injectables
  • Topical

Distribution Channels Covered:

  • Veterinary Clinics and Hospitals
  • Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Canine Arthritis Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Osteoarthritis
  • 5.3 Rheumatoid Arthritis
  • 5.4 Juvenile Idiopathic Arthritis

6 Global Canine Arthritis Treatment Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 6.3 Disease-Modifying Antirheumatic Drugs (DMARDs)
  • 6.4 Corticosteroids
  • 6.5 Nutraceuticals
    • 6.5.1 "" Glucosamine

""

    • 6.5.2 Chondroitin
  • 6.6 Physical Therapy and Rehabilitation
  • 6.7 Stem Cell Therapy
  • 6.8 Surgery
  • 6.9 Other Treatment Types

7 Global Canine Arthritis Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Injectables
  • 7.4 Topical

8 Global Canine Arthritis Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Veterinary Clinics and Hospitals
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies

9 Global Canine Arthritis Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Boehringer Ingelheim Animal Health
  • 11.2 Ceva Sante Animale
  • 11.3 Dechra Pharmaceuticals PLC
  • 11.4 Elanco Animal Health
  • 11.5 Hill's Pet Nutrition
  • 11.6 InVivo Therapeutics Corporation
  • 11.7 Mars Petcare
  • 11.8 Merck Animal Health
  • 11.9 Norbrook Laboratories
  • 11.10 Nutramax Laboratories, Inc.
  • 11.11 OrthoPets LLC
  • 11.12 Rejuvenate Bio
  • 11.13 Royal Canin
  • 11.14 Veterinary Orthopedic Implants Inc.
  • 11.15 Vetoquinol S.A.
  • 11.16 Virbac
  • 11.17 Zoetis Inc.

List of Tables

  • Table 1 Global Canine Arthritis Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Canine Arthritis Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Canine Arthritis Treatment Market Outlook, By Osteoarthritis (2021-2030) ($MN)
  • Table 4 Global Canine Arthritis Treatment Market Outlook, By Rheumatoid Arthritis (2021-2030) ($MN)
  • Table 5 Global Canine Arthritis Treatment Market Outlook, By Juvenile Idiopathic Arthritis (2021-2030) ($MN)
  • Table 6 Global Canine Arthritis Treatment Market Outlook, By Treatment Type (2021-2030) ($MN)
  • Table 7 Global Canine Arthritis Treatment Market Outlook, By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) (2021-2030) ($MN)
  • Table 8 Global Canine Arthritis Treatment Market Outlook, By Disease-Modifying Antirheumatic Drugs (DMARDs) (2021-2030) ($MN)
  • Table 9 Global Canine Arthritis Treatment Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 10 Global Canine Arthritis Treatment Market Outlook, By Nutraceuticals (2021-2030) ($MN)
  • Table 11 Global Canine Arthritis Treatment Market Outlook, By Glucosamine (2021-2030) ($MN)
  • Table 12 Global Canine Arthritis Treatment Market Outlook, By Chondroitin (2021-2030) ($MN)
  • Table 13 Global Canine Arthritis Treatment Market Outlook, By Physical Therapy and Rehabilitation (2021-2030) ($MN)
  • Table 14 Global Canine Arthritis Treatment Market Outlook, By Stem Cell Therapy (2021-2030) ($MN)
  • Table 15 Global Canine Arthritis Treatment Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 16 Global Canine Arthritis Treatment Market Outlook, By Other Treatment Types (2021-2030) ($MN)
  • Table 17 Global Canine Arthritis Treatment Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 18 Global Canine Arthritis Treatment Market Outlook, By Oral (2021-2030) ($MN)
  • Table 19 Global Canine Arthritis Treatment Market Outlook, By Injectables (2021-2030) ($MN)
  • Table 20 Global Canine Arthritis Treatment Market Outlook, By Topical (2021-2030) ($MN)
  • Table 21 Global Canine Arthritis Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 22 Global Canine Arthritis Treatment Market Outlook, By Veterinary Clinics and Hospitals (2021-2030) ($MN)
  • Table 23 Global Canine Arthritis Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 24 Global Canine Arthritis Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.